🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524856-73-00
Authorised Phase I

A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity

2025-524856-73-00 · tracked via the Priya Life Science EU tracker
Sponsor
F. Hoffmann-La Roche AG
Sponsor type
Pharmaceutical company
Therapeutic area
Population Characteristics
Decision date
11/03/2026
Enrollment target
26
Sites
Netherlands

Condition studied

Not Applicable

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524856-73-00 on CTIS ↗ ← All trials in the EU